Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -30.76
- Piotroski Score 5.00
- Grade Buy
- Symbol (ABBV)
- Company AbbVie Inc.
- Price $200.51
- Changes Percentage (-0.34%)
- Change -$0.69
- Day Low $199.22
- Day High $202.32
- Year High $207.32
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
- Last Earnings 10/30/2024
- Ex-Dividend for 5/16 Dividend 01/15/2025
- Dividend Payable 02/14/2025
- Today N/A
- Next Earnings (Estimated) 01/30/2025
- Fiscal Year End N/A
- Average Stock Price Target $172.00
- High Stock Price Target $228.00
- Low Stock Price Target $127.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $3.35
- Trailing P/E Ratio 50.57
- Forward P/E Ratio 50.57
- P/E Growth 50.57
- Net Income $4.86 B
Income Statement
Quarterly
Annual
Latest News of ABBV
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Is AbbVie Inc. (ABBV) the Best Pharma Stock to Buy Right Now?
The pharmaceutical industry is booming, with a focus on innovative research and development. AbbVie Inc. is one of the top pharma stocks to watch. Advances in medical technology and AI are transformin...
By Yahoo! Finance | 3 days ago -
AbbVie (ABBV) Surpasses Q3 Earnings and Revenue Estimates
AbbVie reported quarterly earnings of $3 per share, beating estimates. The company's revenue also exceeded expectations. With a strong performance, investors await management's guidance for future gro...
By Yahoo! Finance | 1 week ago -
AbbVie Has A New Cash Cow As Humira Bows To Skyrizi
AbbVie (ABBV) stock rose as it reported Q3 earnings of $3 per share on $14.46 billion in sales, beating analyst estimates. Sales of new drugs Skyrizi and Rinvoq surpassed expectations, with Skyrizi ou...
By Investor's Business Daily | 1 week ago
